1/16
07:30 am
pfsa
Profusa Launches Lumee™ Tissue Oxygen Healthcare Research Offerings, Initiating First Commercial Revenue
Medium
Report
Profusa Launches Lumee™ Tissue Oxygen Healthcare Research Offerings, Initiating First Commercial Revenue
1/8
07:42 am
pfsa
Profusa Adds Leading Greek Vascular Surgeon to Customer Base [Yahoo! Finance]
Low
Report
Profusa Adds Leading Greek Vascular Surgeon to Customer Base [Yahoo! Finance]
1/8
07:30 am
pfsa
Profusa Adds Leading Greek Vascular Surgeon to Customer Base
Medium
Report
Profusa Adds Leading Greek Vascular Surgeon to Customer Base
12/31
09:22 am
pfsa
Profusa Bolsters European Commercial Network with New French Distributor, MedSell [Yahoo! Finance]
Medium
Report
Profusa Bolsters European Commercial Network with New French Distributor, MedSell [Yahoo! Finance]
12/31
07:30 am
pfsa
Profusa Bolsters European Commercial Network with New French Distributor, MedSell
Low
Report
Profusa Bolsters European Commercial Network with New French Distributor, MedSell
12/30
07:07 pm
pfsa
Profusa Restructures Senior Secured Convertible Notes, Only Convertible Above $0.35 [Yahoo! Finance]
Medium
Report
Profusa Restructures Senior Secured Convertible Notes, Only Convertible Above $0.35 [Yahoo! Finance]
12/30
04:14 pm
pfsa
Profusa (NASDAQ:PFSA) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
High
Report
Profusa (NASDAQ:PFSA) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
12/15
07:46 am
pfsa
Profusa U.S. Study Met Primary End Points as Presented at Late Breaking Clinical Trials at Paris Vascular Insights 2025 [Yahoo! Finance]
High
Report
Profusa U.S. Study Met Primary End Points as Presented at Late Breaking Clinical Trials at Paris Vascular Insights 2025 [Yahoo! Finance]
12/15
07:30 am
pfsa
Profusa U.S. Study Met Primary End Points as Presented at Late Breaking Clinical Trials at Paris Vascular Insights 2025
High
Report
Profusa U.S. Study Met Primary End Points as Presented at Late Breaking Clinical Trials at Paris Vascular Insights 2025
12/11
09:13 am
pfsa
Profusa to Present US-Study Clinical Data at Leipzig Interventional Course (LINC) 2026 [Yahoo! Finance]
Low
Report
Profusa to Present US-Study Clinical Data at Leipzig Interventional Course (LINC) 2026 [Yahoo! Finance]
12/11
08:30 am
pfsa
Profusa to Present US-Study Clinical Data at Leipzig Interventional Course (LINC) 2026
Low
Report
Profusa to Present US-Study Clinical Data at Leipzig Interventional Course (LINC) 2026
11/24
08:15 am
pfsa
Profusa to Present Late Breaking U.S.-Based Clinical Trial Update at Paris Vascular Insights 2025
Medium
Report
Profusa to Present Late Breaking U.S.-Based Clinical Trial Update at Paris Vascular Insights 2025
11/20
01:16 am
pfsa
Profusa (NASDAQ:PFSA) is now covered by analysts at
Weiss Ratings. They set a "sell (e+)" rating on the stock.
High
Report
Profusa (NASDAQ:PFSA) is now covered by analysts at
Weiss Ratings. They set a "sell (e+)" rating on the stock.
11/19
06:42 pm
pfsa
Profusa Announces Third Quarter Business and Financial Highlights [Yahoo! Finance]
High
Report
Profusa Announces Third Quarter Business and Financial Highlights [Yahoo! Finance]
11/19
05:44 pm
pfsa
Profusa Announces Third Quarter Business and Financial Highlights
High
Report
Profusa Announces Third Quarter Business and Financial Highlights
10/30
07:30 am
pfsa
Profusa Outlines Potential Path to $250 Million Revenue by 2030, Driven by Sequential Lumee™ Oxygen and Glucose Monitoring Launches
High
Report
Profusa Outlines Potential Path to $250 Million Revenue by 2030, Driven by Sequential Lumee™ Oxygen and Glucose Monitoring Launches
10/28
08:30 am
pfsa
Profusa Completes Manufacturing Build-Out, On Track to Begin Product Shipments and Revenue in Early 2026
Medium
Report
Profusa Completes Manufacturing Build-Out, On Track to Begin Product Shipments and Revenue in Early 2026
10/22
08:30 am
pfsa
Profusa Expands Sales Footprint with New Distributor for Lumee™ Oxygen Platform in Europe
Medium
Report
Profusa Expands Sales Footprint with New Distributor for Lumee™ Oxygen Platform in Europe